Omeros (OMER) Net Equity Issued and Repurchased (2012 - 2025)

Omeros (OMER) posted Net Equity Issued and Repurchased of -$1.3 million for Q4 2025, down 114.57% sequentially from $9.0 million in Q3 2025.

Analysis

Omeros (OMER) Net Equity Issued and Repurchased (2012 - 2025) Analysis & Trends

Omeros has reported Net Equity Issued and Repurchased for 9 years, with the latest figure at -$1.3 million in Q4 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.7 million (down 85.81% YoY) and the FY2025 annual result came in at $19.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased declined to -$1.3 million in Q4 2025 per OMER's latest filing, from $9.0 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $9.0 million in Q3 2025 and troughed at -$1.3 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	138.43 Bn	130.58 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	63.34 Bn	58.15 Bn	1.37 Bn	-
4	Moderna	57.98 Bn	52.85 Bn	52.00 Mn	-
5	Revolution Medicines	43.98 Bn	43.98 Bn	-	141.90 Mn
6	BeOne Medicines	39.92 Bn	34.82 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.42 Bn	32.11 Bn	992.69 Mn	-
8	Royalty Pharma	28.42 Bn	27.58 Bn	-	-
9	Insmed	27.36 Bn	26.20 Bn	358.27 Mn	-
10	Omeros	1.38 Bn	1.38 Bn	27.73 Mn	-

Historic Data

Download Data